Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
NCT06857955 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
Conditions Studied
Interventions
- OTHER Saline
- DRUG QCZ484
Study Locations (20)
Florida
- Clinical Research of Brandon LLC — Brandon
- ALL Medical Research LLC — Cooper City
- National Research Institute — Hialeah
- Cen Exel RCA — Hollywood
- East Coast Institute for Research — Jacksonville
- Entrust Clinical Research — Miami
- Inpatient Research Clinical LLC — Miami Lakes
- Inpatient Research Clinical LLC — Miami Lakes
- Suncoast Clinical Research — New Port Richey
California
- NICRs Research Center — Garden Grove
- Valiance Clinical Research — Huntington Park
- Downtown L.A. Research Center Inc — Los Angeles
- Clinical Trials Research Sacramento — Sacramento
- Encompass Clinical Research — Spring Valley
Alabama
- SEC Clinical Research LLC — Andalusia
- UAB St Vincents — Birmingham
- Longwood Research — Huntsville
- The Center for Clinical Trials — Saraland
Arizona
- Elite Clinical Studies — Phoenix
- Synexus Clinical Research US Inc — Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2028-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06857955
The ClinicalTrials.gov registry entry for NCT06857955 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 792 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions — of which Saline is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06857955 reports 20 study locations spanning 4 distinct geographic areas — top geographies include Florida, California, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06857955 about?
NCT06857955 is a clinical study titled "A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients". The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension
What is the current status of trial NCT06857955?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 380 participants. The study started on 2025-03-26. Estimated completion is 2028-04-05.
What conditions does trial NCT06857955 study?
This clinical trial studies the following conditions: Hypertension. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06857955?
The interventions under investigation include: Saline (OTHER), QCZ484 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06857955?
This trial is sponsored by Novartis Pharmaceuticals, which has 792 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06857955 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.